Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $1,066,600.00 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the transaction, the senior vice president owned 15,312 shares in the company, valued at $1,633,177.92. This represents a 39.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The stock was sold at an average price of $84.63, for a total value of $846,215.37.
• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The stock was sold at an average price of $80.95, for a total value of $128,467.65.
• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.69, for a total value of $27,527.55.
• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.72, for a total value of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The shares were sold at an average price of $59.07, for a total value of $607,830.30.

Oruka Therapeutics Stock Performance

ORKA opened at $111.04 on Monday. The company has a market capitalization of $7.35 billion, a PE ratio of -54.70 and a beta of -0.34. The stock’s fifty day moving average is $87.52 and its 200-day moving average is $62.81. Oruka Therapeutics, Inc. has a one year low of $14.08 and a one year high of $111.37.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, equities research analysts forecast that Oruka Therapeutics, Inc. will post -2.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Barclays raised their price objective on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research report on Monday, April 27th. Wedbush reissued an “outperform” rating and set a $165.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. HC Wainwright restated a “buy” rating and set a $120.00 target price on shares of Oruka Therapeutics in a report on Monday, August 3rd. Guggenheim restated a “buy” rating and issued a $200.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Finally, Weiss Ratings raised Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $134.30.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. acquired a new position in Oruka Therapeutics in the 1st quarter worth approximately $2,505,000. JPMorgan Chase & Co. raised its stake in Oruka Therapeutics by 567.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock valued at $173,000 after purchasing an additional 13,115 shares during the period. Legal & General Group Plc purchased a new stake in shares of Oruka Therapeutics in the second quarter valued at $28,000. Rhumbline Advisers purchased a new stake in shares of Oruka Therapeutics in the second quarter valued at $320,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Oruka Therapeutics in the second quarter worth $96,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.